Tag Archives: Amneal Pharms. LLC v. Almirall

Even If the Federal Circuit Could Award Attorney Fees for IPR Appeals, § 285 Does Not Permit It to Award Fees Incurred During the IPR

By Squire Patton Boggs on June 11, 2020 Posted in Life Sciences Biotech Pharma, Patent Litigation

Normally, a branded bio/pharm company is pleased to escape an inter partes review (IPR) unscathed. Doubly so when the challenger moves voluntarily to dismiss its appeal. So what happened in Amneal Pharms. LLC v. Almirall, LLC, No. 20-1106, to cause Almirall to insist on receiving its attorney fees for a mere month of work before … Continue Reading